Haematology - Multiple Myeloma

A list of our early phase haematology (Multiple Myeloma) trials which are open to recruitment at University College London Hospitals.

ProMMise

A Platform trial for Relapsed patients to evaluate Ongoing novel therapies in Multiple Myeloma In combination with Standard of care therapies

IRAS Number:1003553
Principal Investigator:Dr. Rakesh Popat
Drug Class/ Treatment:Benlantamab Mafodotin (Anti-BCMA IgG1 Antibody-Drug Conjugate)
Patient Population:Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

DTP3

Treating Multiple Myeloma and Diffuse Large B Cell Lymphoma by Targeting the NFκB Pathway with the First-in-Class GADD45β/MKK7 Inhibitor, DTP3

IRAS Number:1004023
Principal Investigator:Dr Rakesh Popat
Drug Class/ Treatment:DTP3 (GADD45β/MKK7 Inhibitor)
Patient Population:Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

79635322MMY1001

Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma

IRAS Number:1006143
Principal Investigator:Dr Rakesh Popat
Drug Class/ Treatment:JNJ-79635322 - Trispecific Antibody
Patient Population:Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

TCD17710

First-in-human, open-label Phase 1/2 study to investigate safety and efficacy of SAR445514, an NK-cell engager (NKCE) targeting B-cell mat ration antigen (BCMA) in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and in relapsed/refractory lightchain amyloidosis (RRLCA)

IRAS Number:1007232
Principal Investigator:Dr Rakesh Popat
Drug Class/ Treatment:SAR445514 (NK-Cell Engager (NKCE) Targeting BCMA)
Patient Population:Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

BGB-11417-105

A phase 1b/2 Dose-Escalation and Cohort-Expansion Study to determine the Safety and Efficacy of BGB11417 as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)

IRAS Number:1005586
Principal Investigator:Dr Rakesh Popat
Drug Class/ Treatment:

BGB-11417 (BCL2 Inhibitor)

Monotherapy, In Combination with Dexamethasone and In Combination with Dexamethasone/Carfilzomib

Patient Population:Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

M24-108

A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma

IRAS Number:1006892
Principal Investigator:Dr Rakesh Popat
Drug Class/ Treatment:ABBV-383 (B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody)
Patient Population:Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)
On-hold to recruitment
CA057-003 (CC-92480)
An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants with Relapsed or Refractory Multiple Myeloma
IRAS Number:1005265
Principal Investigator:Dr Rakesh Popat
Drug Class/ Treatment:Mezigdomide (CC-92480) - Cereblon (CRBN) E3 Ligase Modulating Drug (CELMoD)
Patient Population:Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

Principal Investigator(s)

Dr. Rakesh Popat Profile Photo
Dr Rakesh Popat

Consultant Haematologist